Core 2: Neuro-Imaging Core

核心2：神经成像核心（NIC） 总结/摘要 胶质母细胞瘤（GBM）的极差预后和缺乏有效治疗仍然是一个重要的问题。 公共卫生问题。虽然传统的MRI技术在确定GBM对常见肿瘤的反应方面很有价值， 抗肿瘤治疗、包括免疫治疗的新治疗、抗血管生成剂或治疗 改变肿瘤代谢可能导致放射学改变， 反应性或生长性肿瘤。因此，神经成像核心（NIC）的主要目标是提供 先进的MRI和PET成像支持，与SPORE项目具有既定的可靠性和一致性 他们各自的研究项目。具体而言，NIC将使用定量MRI和PET进行预处理。 临床成像（目标1）和最先进的MR和PET成像采集，先进的后处理，以及 用于新型临床试验中患者临床成像的新型分析工具（目标2）。因此，本核心将增加 通过帮助研究者更好地了解原位代谢、生理和 传统的放射学改变在大脑和肿瘤，以解决具体目标的每一个 加州大学洛杉矶分校脑癌孢子项目NIC的另一个主要目标是了解 代谢和/或生理成像和肿瘤生物学，以便可靠地描绘治疗反应 与复发性肿瘤（目标3）相比，这反过来将有助于直接翻译新的MR-PET伴侣 生物标志物/技术应用于临床，用于评估正在进行的和新的治疗反应。 来自SPORE项目和核心的临床试验。

Core 2: Neuro-Imaging Core (NIC) SUMMARY/ABSTRACT The extremely poor prognosis and lack of effective treatments for glioblastoma (GBM) remains a significant public health issue. While traditional MRI techniques are valuable in determining GBM response to common anti-neoplastic therapies, novel treatments including immunotherapies, anti-angiogenic agents, or therapies that alter tumor metabolism may result in radiographic changes that are challenging to differentiate from non- responsive or growing tumor. Therefore, the primary goal of the Neuro-Imaging Core (NIC) will be to provide advanced MRI and PET imaging support with established reliability and consistency to SPORE project investigators for their respective projects. Specifically, the NIC will use quantitative MRI and PET for pre- clinical imaging (Aim 1) and state-of-the-art MR and PET imaging acquisition, advanced post-processing, and novel analysis tools for clinical imaging of patients in novel clinical trials (Aim 2). Hence, this Core will add value to the overall SPORE by helping investigators to better understand the in situ metabolic, physiologic, and traditional radiographic changes within the brain and tumor in order to address specific objectives of each of the UCLA Brain Cancer SPORE projects. Another main goal of the NIC is to understand the link between metabolic and/or physiologic imaging and tumor biology in order to reliably delineate treatment response versus recurrent tumor (Aim 3), which in turn will facilitate the direct translation of new MR-PET companion biomarkers/techniques to the clinic for the evaluation of treatment response in ongoing and new therapeutic clinical trials resulting from the SPORE projects and cores.